Results Presented at the ADA 69th Scientific Sessions Demonstrate that INCB13739, Incyte`s Oral 11beta-HSD1 Inhibitor, Significantly Improves Glycemic Control, Insulin Sensitivity and Total Cholesterolin Patients with Type 2 Dia